Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial.

G BellinganF JaconoJ Bannard-SmithD BrealeyN MeyerD ThickettD YoungA BentleyB J McVerryR G WunderinkK C DoerschugC SummersM RojasAnthony E TingE D Jenkins

Published in: Intensive care medicine (2021)

Multipotent adult progenitor cells were safe and well tolerated in ARDS. The clinical outcomes warrant larger trials to evaluate the therapeutic efficacy and optimal patient population.

Keyphrases

acute respiratory distress syndrome
double blind
placebo controlled
extracorporeal membrane oxygenation
mechanical ventilation
clinical trial
study protocol
phase iii
phase ii
phase ii study
randomized controlled trial
childhood cancer
intensive care unit
open label
cross sectional